Gink­go snaps up gene ther­a­py vec­tor as­sets from Stride­Bio

Gink­go Bioworks is pick­ing up some vi­ral vec­tors, part of what it calls an on­go­ing push in­to gene ther­a­py ser­vices.

On Wednes­day, Gink­go an­nounced that it will ac­quire Stride­Bio’s ade­no-as­so­ci­at­ed virus (AAV) cap­sid as­sets, which are in the dis­cov­ery or pre­clin­i­cal stage and cen­tered around car­dio­vas­cu­lar dis­eases, ac­cord­ing to Stride­Bio’s web­site. Gink­go said in the re­lease that these as­sets are avail­able to li­cense out or part­ner on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER